- Home
- AMBO vs CYCC Comparison
AMBO vs CYCC Comparison
Compare AMBO & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- CYCC
- Stock Information
- Founded
- AMBO 2000
- CYCC 1992
- Country
- AMBO United States
- CYCC Malaysia
- Employees
- AMBO N/A
- CYCC N/A
- Industry
- AMBO Other Consumer Services
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- CYCC Health Care
- Exchange
- AMBO Nasdaq
- CYCC Nasdaq
- Market Cap
- AMBO 8.8M
- CYCC 7.8M
- IPO Year
- AMBO 2010
- CYCC N/A
- Fundamental
- Price
- AMBO $2.79
- CYCC $3.77
- Analyst Decision
- AMBO
- CYCC
- Analyst Count
- AMBO 0
- CYCC 0
- Target Price
- AMBO N/A
- CYCC N/A
- AVG Volume (30 Days)
- AMBO 5.9K
- CYCC 504.4K
- Earning Date
- AMBO 01-01-0001
- CYCC 08-13-2025
- Dividend Yield
- AMBO N/A
- CYCC N/A
- EPS Growth
- AMBO N/A
- CYCC N/A
- EPS
- AMBO 0.11
- CYCC N/A
- Revenue
- AMBO $9,392,000.00
- CYCC $14,000.00
- Revenue This Year
- AMBO N/A
- CYCC $137.21
- Revenue Next Year
- AMBO N/A
- CYCC N/A
- P/E Ratio
- AMBO $23.27
- CYCC N/A
- Revenue Growth
- AMBO 2.50
- CYCC N/A
- 52 Week Low
- AMBO $1.00
- CYCC $3.08
- 52 Week High
- AMBO $5.55
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- AMBO 56.76
- CYCC 23.83
- Support Level
- AMBO $2.34
- CYCC $3.08
- Resistance Level
- AMBO $2.70
- CYCC $3.97
- Average True Range (ATR)
- AMBO 0.20
- CYCC 0.52
- MACD
- AMBO 0.04
- CYCC 1.32
- Stochastic Oscillator
- AMBO 80.25
- CYCC 5.54
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.